Wall Street Zen Downgrades Rigel Pharmaceuticals to 'Hold'

Analysts cite concerns over the company's financial performance and outlook.

Mar. 14, 2026 at 6:04am

Got story updates? Submit your updates here. ›

Investment research firm Wall Street Zen has downgraded Rigel Pharmaceuticals (NASDAQ:RIGL) from a 'buy' rating to a 'hold' rating in a new report. The move comes as analysts express caution over the biotechnology company's recent financial results and future prospects.

Why it matters

Rigel Pharmaceuticals is a key player in the pharmaceutical industry, focused on developing treatments for immune, hematologic, and oncologic diseases. The downgrade from Wall Street Zen could impact investor sentiment and the company's stock price, potentially affecting its ability to raise capital and fund future research and development efforts.

The details

In the report, Wall Street Zen analysts cited concerns over Rigel Pharmaceuticals' financial performance, including a miss on earnings estimates in its most recent quarter. The analysts also expressed uncertainty about the company's ability to achieve its long-term growth targets and successfully commercialize its lead drug, Tavalisse, for the treatment of chronic immune thrombocytopenia.

  • Rigel Pharmaceuticals reported its latest quarterly earnings on March 3, 2026.
  • Wall Street Zen issued its downgrade report on March 14, 2026.

The players

Rigel Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing treatments for immune, hematologic, and oncologic diseases.

Wall Street Zen

An investment research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What they’re saying

“We must downgrade Rigel Pharmaceuticals to a 'hold' rating due to concerns over the company's recent financial performance and the uncertain outlook for its lead drug, Tavalisse.”

— Wall Street Zen Analyst (Wall Street Zen)

What’s next

Investors will be closely watching Rigel Pharmaceuticals' future financial reports and any updates on the commercialization of Tavalisse to see if the company can address the concerns raised by Wall Street Zen.

The takeaway

The downgrade of Rigel Pharmaceuticals by Wall Street Zen highlights the challenges facing smaller biotechnology companies as they work to bring new treatments to market and maintain investor confidence. The company's ability to navigate these challenges will be crucial to its long-term success.